Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 337 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Qué debe saber sobre las pruebas de ADN en el hogar... February 8, 2023 Foodie Friday: It’s Berry Season! July 30, 2021 Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and... November 8, 2022 Spotlight On: Occupational Therapists in Cancer Care November 4, 2021 Load more HOT NEWS Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... EMA Recommends Granting a Marketing Authorisation for Poherdy Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical...
